TY - JOUR
T1 - Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
AU - Hanker, L. C.
AU - El-Balat, A.
AU - Drosos, Z.
AU - Kommoss, S.
AU - Karn, T.
AU - Holtrich, U.
AU - Gitas, G.
AU - Graeser-Mayer, M.
AU - Anglesio, M.
AU - Huntsman, D.
AU - Rody, A.
AU - Gevensleben, H.
AU - Hoellen, F.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/5
Y1 - 2021/5
N2 - Purpose: Sphingosine-kinase-1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in ovarian cancer pathogenesis, progression and mechanisms of drug resistance. It is overexpressed in a variety of cancer subtypes. We investigated SPHK1 expression as a prognostic factor in epithelial ovarian cancer patients. Methods: Expression analysis of SPHK1 was performed on formalin-fixed paraffin-embedded tissue from 1005 ovarian cancer patients with different histological subtypes using immunohistochemistry. Staining intensity of positive tumor cells was assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. Results: In our ovarian cancer collective, high levels of SPHK1 expression correlated significantly with complete surgical tumor resection (p = 0.002) and lower FIGO stage (p = 0.04). Progression-free and overall survival were further significantly longer in patients with high-grade serous ovarian cancer and overexpression of SPHK1 (p = 0.002 and p = 0.006, respectively). Conclusion: Our data identify high levels of SPHK1 expression as a potential favorable prognostic marker in ovarian cancer patients.
AB - Purpose: Sphingosine-kinase-1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in ovarian cancer pathogenesis, progression and mechanisms of drug resistance. It is overexpressed in a variety of cancer subtypes. We investigated SPHK1 expression as a prognostic factor in epithelial ovarian cancer patients. Methods: Expression analysis of SPHK1 was performed on formalin-fixed paraffin-embedded tissue from 1005 ovarian cancer patients with different histological subtypes using immunohistochemistry. Staining intensity of positive tumor cells was assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. Results: In our ovarian cancer collective, high levels of SPHK1 expression correlated significantly with complete surgical tumor resection (p = 0.002) and lower FIGO stage (p = 0.04). Progression-free and overall survival were further significantly longer in patients with high-grade serous ovarian cancer and overexpression of SPHK1 (p = 0.002 and p = 0.006, respectively). Conclusion: Our data identify high levels of SPHK1 expression as a potential favorable prognostic marker in ovarian cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=85102074189&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/476178fa-275e-3436-bba4-d5514f1b6fd8/
U2 - 10.1007/s00432-021-03558-x
DO - 10.1007/s00432-021-03558-x
M3 - Journal articles
C2 - 33660008
AN - SCOPUS:85102074189
SN - 0171-5216
VL - 147
SP - 1421
EP - 1430
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 5
ER -
